Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. - Wikidata - awgldk - TriplyDB

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

http://www.wikidata.org/entity/Q34236901

about

BRCAness: finding the Achilles heel in ovarian cancer Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies Novel therapeutic strategies for patients with triple-negative breast cancer A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model Single cell resolution in vivo imaging of DNA damage following PARP inhibition Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.Investigational agents in development for the treatment of ovarian cancer A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer Current and future systemic treatment options in metastatic pancreatic cancer.ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.Treating breast cancer in the 21st century: emerging biological therapies The promise and peril of chemical probes.Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.Familial breast cancer - targeted therapy in secondary and tertiary prevention Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105 Advances in small-molecule drug discovery for triple-negative breast cancer.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?Ovarian cancer: in search of better marker systems based on DNA repair defects Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes.Population and target considerations for triple-negative breast cancer clinical trials.SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.Synthetic genetic targeting of genome instability in cancer.A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines Structural Implications for Selective Targeting of PARPs.DNA repair in cancer: emerging targets for personalized therapy.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Novel targeted agents for the treatment of advanced breast cancer.Targeted therapy for triple-negative breast cancer: where are we?Cancer treatment according to BRCA1 and BRCA2 mutations.PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.PARP inhibitors in cancer therapy: an update.A review of iniparib in ovarian cancer.

P2860

Q24630872-6B688837-C87F-4867-B168-936561531030 Q26863501-23995542-B385-4691-ACA3-44219CA976A7 Q27027503-C5FB1A5A-7381-42EA-A9F3-AB4F7E943268 Q28067436-E588282A-5D90-44F0-9647-B8A4F3719135 Q28550119-F5502D73-BB09-44C6-96CE-1AA6934A6498 Q30650918-34DEE245-3962-42C4-B00E-4B21F2FD6580 Q33607384-4611384F-9462-4944-99CE-0BE65B762325 Q33874621-949622B2-881B-4BB3-A752-69FB05A70FA1 Q33906319-294AE794-B2AB-455D-AD8F-4879DC24D654 Q33920800-CD63892B-D709-40FF-84B3-61DBCB6FD9B1 Q33946208-F2D28E09-3787-48C4-AF30-BFCB91DC1E53 Q33948033-06C625EE-7F24-48BF-9E48-34A15895037E Q34249365-21211F23-5DB5-40F9-AED0-4584EB27B61C Q34326536-908CE062-6276-4971-B124-31A7531D4EAF Q34486195-3C30D6FB-0817-40BC-AED8-14C5A56AE432 Q34520145-9FD392D2-5B0B-4A9F-8B0B-2568845AC6B9 Q35399626-DDCBA401-CA78-4D54-A23F-ED7F43158814 Q35671356-588F2584-4312-46C4-A59E-901467DF324D Q35818491-DBF6F340-1095-4C25-B606-32C881FCE1FB Q35895214-2ED783E1-23F1-40AC-BEA8-31C8FB73825C Q36280791-F7E91FE5-9486-416F-AF6E-A876B56483DF Q36490203-207EBD20-E8A8-42EE-B196-96E4CD77FD2C Q36589947-27D704EC-D5AF-4B00-A97B-F311E9127993 Q36908133-99829DFA-8232-4318-98D5-3AC9AB574AE3 Q36913813-80644C1B-D544-4B9A-84FE-EB874343D469 Q36914317-CFA2F8DC-A2F8-488D-9141-66ABDA570422 Q37148642-F755D8A2-3629-46BA-81B8-CEAD623512CF Q37220528-E7F4F460-31F4-4EAF-B0AA-AA98CF7C9B95 Q37226478-89DCBE22-604C-4BB8-9C8E-B231B3FC6EAE Q37228176-D31E88C3-54BA-438B-84E8-5458828366C1 Q37269217-A088A761-3D81-4C83-8554-99E8C80DDCA3 Q37405386-DE2AA03E-3FA3-4139-B8BE-8EAD7B1BDA93 Q37600799-6BF69296-B468-44D1-BA43-942924FBE4FF Q37607283-67B98FC9-4B07-47CB-964A-30BBF42C63B9 Q38008723-28DBD16D-7952-4293-9830-AEAD0566B4E4 Q38009760-79AEC743-CA8F-43E3-87C7-8E192ABBDCD6 Q38028798-2DA33829-5EF5-400D-988D-B453DFBC9D7F Q38029726-8286FE03-9104-45DB-8481-13F367D6F720 Q38078993-74D47B66-8231-48EA-8C95-F6DE24F23347 Q38080153-16E63996-433D-465F-823B-E6CE58CD6030

P2860

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

http://www.wikidata.org/entity/Q34236901

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.

@ast

Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.

@en

Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.

@nl

type

label

Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.

@ast

Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.

@en

Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.

@nl

prefLabel

Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.

@ast

Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.

@en

Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.

@nl

P1433

Q34236901-B3EFE7FC-BFCC-4A12-AE9C-48C28424DE58

P1476

Q34236901-57FD0C7D-7AF3-4708-A618-484ADD44C6EE

P2093

Q34236901-173F21D8-4AF9-4E3F-BA76-ADA09BED4DFC

Q34236901-18669128-4D44-48B2-A3A4-56A3AFC0B76A

Q34236901-3067BFB4-CDA0-4A21-9BD2-D03A71FDDF0C

Q34236901-30EECB18-055E-4DD4-A2B8-E9EAE4FCF272

Q34236901-4060D1A6-D5F9-4CCF-9F74-638F89596CDA

Q34236901-44B689E4-909B-489F-8505-DB163337189F

Q34236901-4C9C3310-D550-4A77-949C-7E2E28D6A78F

Q34236901-4DAFE585-7FD5-4946-B944-BD943760721C

Q34236901-703ED6CA-6E41-4CB2-9D4A-3376C852436D

Q34236901-89026EC8-FE0F-415A-B6A5-69C1C05D055C

P304

Q34236901-8A2F0F87-D8CB-4393-ABA5-BAA47C9D8C9F

P31

Q34236901-3C6042CD-C7F1-4BCE-B5B4-575CF41AAEA2

P356

Q34236901-661A6BA7-77F0-4291-A953-6A6C771D326A

P407

Q34236901-87B73A58-9BC3-4100-803F-4931639B323F

P433

Q34236901-B40CC4C2-ACCC-4ACC-94B7-B8F6FA06A301

P478

Q34236901-3B48EB32-05CD-4735-AEC1-F57C8B9A88E7

P577

Q34236901-F3F546E9-653C-46FA-8251-38994F227907

P698

Q34236901-1060D910-83CA-4145-8705-D6814A52D7F2

P356

1078-0432.CCR-11-1973

P1433

Clinical Cancer Research

P1476

Iniparib nonselectively modifi ...... ot a bona fide PARP inhibitor.

@en

P2093

Alexander R Shoemaker

http://www.w3.org/2001/XMLSchema#string

Allison J Xu

http://www.w3.org/2001/XMLSchema#string

Bruce W Surber

http://www.w3.org/2001/XMLSchema#string

Cherrie K Donawho

http://www.w3.org/2001/XMLSchema#string

Damien B Ready

http://www.w3.org/2001/XMLSchema#string

David X Maag

http://www.w3.org/2001/XMLSchema#string

Eric F Johnson

http://www.w3.org/2001/XMLSchema#string

Joann P Palma

http://www.w3.org/2001/XMLSchema#string

John E Harlan

http://www.w3.org/2001/XMLSchema#string

Larry R Solomon

http://www.w3.org/2001/XMLSchema#string

P304

510-523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-1973

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22128301

http://www.w3.org/2001/XMLSchema#string